Trial · NCT07899359
Immunotherapy for Curing Toddlers With Severe Food Allergy - a Paradigm Shift From Passive to Active Treatment With Multi-allergen Oral Immunotherapy
NCT07899359, Not applicable, Not yet recruiting, Odense University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Immunotherapy for Curing Toddlers With Severe Food Allergy - a Paradigm Shift From Passive to Active Treatment With Multi-allergen Oral Immunotherapy. Trials, record NCT07899359. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899359
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Immunotherapy for Curing Toddlers With Severe Food Allergy - a Paradigm Shift From Passive to Active Treatment With Multi-allergen Oral Immunotherapy
- NCT number
- NCT07899359
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Odense University Hospital
- Conditions
- Food Allergy in Children
- Interventions
- OIT multiallergen powder, Placebo powder
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of patients with tolerance to 900 mg protein at a food challenge in the clinic after 1 year in alle groups. | 1 year | The outcome of a food challenge is dichotome: tolerance to 900mg or not (= negative or positive provocation) A food challenge is a standardised procedure: Increasing amounts of protein powder is given to the child every 30 minutes until the 900 mg is reached (= tolerance) or until the child has an objective allergic reaction (=positiv food challenge). An objective allergic reaction is a clinical diagnosis. In case of an allergic reaction, the cumulative dose of ingested allergen and the observed symptoms are registered. |
| Secondary | Number of children with tolerance to 900 mg protein at a food challenge in the clinic after two years in group A and B | 2 years | The outcome of a food challenge is dichotome: tolerance to 900mg or not (= negative or positive provocation) A food challenge is a standardised procedure: Increasing amounts of protein powder is given to the child every 30 minutes until the 900 mg is reached (= tolerance) or until the child has an objective allergic reaction (=positiv food challenge). An objective allergic reaction is a clinical diagnosis. In case of an allergic reaction, the cumulative dose of ingested allergen and the observed symptoms are registered. |
| Secondary | Immunological biomarkers | 2 years | Changes in immunological markers (specific IgE, IgG, T-cell populations, plasma proteins, feces microbiota, and metabolites etc.) in relation to interventions |
| Secondary | comorbidities | 2 years | Number of children with eczema and asthma in all groups after 0,1 and 2 years |
| Secondary | Difference in Quality of life between groups measured by a questionnaire | 2 years | In all groups, the parents will fullfill the questionnaire FAQLQ-PF after 0, 1 and 2 years to compare QoL. The hypothesis is that the intervention is associated with a higher FAQLQ-PF-score than the placebo group. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899359
GET https://conductscience.org/api/trials/v1/NCT07899359/registered